NAXE

Across TCGA pan-cancer cohorts, NAXE mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NAXE data layer compared with 28 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NAXE mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NAXE expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, HNSC, and CCRCC are the cancer types where NAXE mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	1.000	0.667	.003	18	view →
HNSC	DFS	Quartile	All	0.355	0.903	.010	12	view →
CCRCC	DFS	Quartile	III,IV	0.140	0.915	.017	6	view →
LSCC	OS	Quartile	II,III,IV	1.000	0.779	.038	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NAXE–PDAC (OS)

Open the PDAC breakdown →